Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

By M. Pfreundschuh, L. Trümper, M. Kloess, R. Schmits, A. Feller, C. Rübe, C. Rudolph, M. Reiser, D. Hossfeld, H. Eimermacher and 3 more. Blood, 2004

743 citations recorded by the source corpus.

Subfields: Oncology, Pathology and Forensic Medicine, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/aed825dde79284045fd0dc70eb5a7b6595aeede7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. P. Feugier
2. H. Tilly
3. A. Hoof
4. C. Gisselbrecht
5. C. Sebban
6. B. Coiffier
7. P. Solal-Céligny
8. R. Bouabdallah

Citations in the corpus

• Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. (2005, positive): “Although difficult to perform in elderly patients, dose intensification of the CHOP regimen by increasing doses or shortening the administration schedule with G-CSF support could be another way to increase the CR rate and to decrease the relapse rate.(5,26,27)”
• Repopulation of cancer cells during therapy: an important cause of treatment failure (2005, neutral): “gov/cancertopics/pdq/treatment/adult-non-hodgkins/healthprofessional">non-Hodgkin's lymphoma”